Fig. 2: Prognostic value of individual HER2DX biological signatures and composite score. | Nature Communications

Fig. 2: Prognostic value of individual HER2DX biological signatures and composite score.

From: HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

Fig. 2

A Heatmap of percentile scores for immune, luminal, and proliferation signatures across 154 tumors profiled in Trans-RESPECT, illustrating biological heterogeneity. Correlation coefficients (r) between two signatures are shown below the heatmap. In addition, HER2DX risk scores are shown for each patient. B Table showing hazard ratios (HRs) for RFS and OS across the three HER2DX biological signatures, immune/IGG, luminal, and proliferation, and TILs evaluated in the full cohort and in the node-negative subgroup. Sensitivity analyses are shown using different censoring timepoints (5–10 years and uncensored [U*]). Favorable HRs (below 1.0) are highlighted in green, while unfavorable HRs (above 1.0) are in red. C Kaplan–Meier curve showing 10-year RFS by composite score (0 to 3 favorable biological signatures). D Kaplan–Meier curve showing 10-year OS by composite score. The composite score assigns one point for each favorable feature: immune-high, luminal-high, and proliferation-low. E Boxplots showing the association between TIL levels and each HER2DX biological signature (IGG/immune, luminal, proliferation). P values are derived from Kruskal–Wallis tests.

Back to article page